MedTrace Logo

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT05209100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2026-04-03

No results posted yet for this study

Summary

This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease. In parallel, the investigators will establish a biobank that will allow future studies to reveal how encroachment is connected to host metabolism and liver physiology, including the composition and function of the fecal microbiome.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

PROCEDURE

Sigmoidoscopy

During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.

Sponsors & Collaborators

  • AdventHealth Translational Research Institute

    lead OTHER

Principal Investigators

  • Karen Corbin, PhD, RD · Investigator

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-11
Primary Completion
2023-03-22
Completion
2023-03-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05209100 on ClinicalTrials.gov